Artelo Biosciences Inc. [NASDAQ: ARTL] gained 22.37% on the last trading session, reaching $1.86 price per share at the time. The company report on March 9, 2021 that Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors.
Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors.
“We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice and insight will be instrumental to the Company’s development and growth.”.
Artelo Biosciences Inc. represents 15.71 million in outstanding shares, while the company has a total market value of $29.98 million with the latest information. ARTL stock price has been found in the range of $1.575 to $2.10.
If compared to the average trading volume of 9.53M shares, ARTL reached a trading volume of 3705495 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Artelo Biosciences Inc. [ARTL]:
Ladenburg Thalmann have made an estimate for Artelo Biosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 12, 2021.
The Average True Range (ATR) for Artelo Biosciences Inc. is set at 0.37 The Price to Book ratio for the last quarter was 2.09, with the Price to Cash per share for the same quarter was set at 0.46.
Trading performance analysis for ARTL stock
Artelo Biosciences Inc. [ARTL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.00. With this latest performance, ARTL shares gained by 57.63% in over the last four-week period, additionally plugging by 151.35% over the last 6 months – not to mention a rise of 86.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARTL stock in for the last two-week period is set at 52.58, with the RSI for the last a single of trading hit 51.16, and the three-weeks RSI is set at 54.06 for Artelo Biosciences Inc. [ARTL]. The present Moving Average for the last 50 days of trading for this stock 1.4014, while it was recorded at 1.6460 for the last single week of trading, and 1.0548 for the last 200 days.
Artelo Biosciences Inc. [ARTL]: A deeper dive into fundamental analysis
Return on Total Capital for ARTL is now -100.38, given the latest momentum, and Return on Invested Capital for the company is -99.72. Return on Equity for this stock declined to -99.72, with Return on Assets sitting at -85.73.
Reflecting on the efficiency of the workforce at the company, Artelo Biosciences Inc. [ARTL] managed to generate an average of -$1,551,621 per employee.Artelo Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.40 and a Current Ratio set at 15.40.
Artelo Biosciences Inc. [ARTL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Artelo Biosciences Inc. posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.53/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 24.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARTL.
An analysis of insider ownership at Artelo Biosciences Inc. [ARTL]
There are presently around $0 million, or 18.00% of ARTL stock, in the hands of institutional investors. The top three institutional holders of ARTL stocks are: GEODE CAPITAL MANAGEMENT, LLC with ownership of 60,877, which is approximately New of the company’s market cap and around 7.82% of the total institutional ownership; NORTHERN TRUST CORP, holding 12,516 shares of the stock with an approximate value of $19000.0 in ARTL stocks shares; and CREDIT SUISSE AG/, currently with $18000.0 in ARTL stock with ownership of nearly New of the company’s market capitalization.
Positions in Artelo Biosciences Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 4 institutional holders increased their position in Artelo Biosciences Inc. [NASDAQ:ARTL] by around 85,339 shares. Additionally, 1 investors decreased positions by around 162 shares, while 0 investors held positions by with 144 shares. The mentioned changes placed institutional holdings at 85,357 shares, according to the latest SEC report filing. ARTL stock had 3 new institutional investments in for a total of 85,268 shares, while 1 institutional investors sold positions of 162 shares during the same period.